CytoDyn to Hold Webcast to Provide Company Update
CytoDyn Inc. (OTCQB: CYDY) announced a webcast for the investment community on March 31, 2022, featuring key executives, including Board Chair Tanya Urbach and CFO Antonio Migliarese.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CytoDyn Inc. (OTCQB: CYDY) announced a webcast for the investment community on March 31, 2022, featuring key executives, including Board Chair Tanya Urbach and CFO Antonio Migliarese. The session aims to update stakeholders on the company's developments concerning leronlimab, a CCR5 antagonist with potential for various therapeutic uses. Participants can submit questions beforehand at ir@cytodyn.com. The event will begin at 5:30 am PT / 8:30 am ET, with a recorded replay available until April 30, 2022.
Positive
- Webcast scheduled for March 31, 2022, to update investors on company developments.
- Key executives participating in the presentation.
Negative
- None.
Details
News Market Reaction – CYDY
The recorded move for CYDY in the trading session of this news was +0.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations, will host an investment community webcast to provide an update on developments at the Company on Thursday, March 31, 2022.
Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.
| Date: | Thursday, March 31, 2022 |
| Time: | 5:30 am PT / 8:30 am ET |
| Access: | https://services.choruscall.com/mediaframe/webcast.html?webcastid=v9IRoWUq |
| Questions: | Prior to the webcast, questions can be submitted online to ir@cytodyn.com |
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until April 30, 2022.
CONTACTS
Investors:
Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com
Media:
Dan Zacchei / Joe Germani
Sloane & Company
dzacchei@sloanepr.com / jgermani@sloanepr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.